Patent · US Active

Vaccinia virus mutants containing the major genomic deletions of MVA

US8859257B2 · kind B2 · utility

0Cited by

0References

23Claims

0Family size

Assignee

Bavarian Nordic A/S · DK

Inventors

Jürgen Hausmann · Gundelfingen, DE
Christine Meisinger-Henschel · Schwanau, DE
Mark Suter · Luzern, CH

Key dates

Filing date	Jan 28, 2011
Grant date	Oct 14, 2014
Priority date	—
Expiry date	Mar 15, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/24162
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides modified vaccinia virus (VACV) genomes as well as vectors, especially viral vectors comprising the same. The present invention further provides modified vaccinia viruses. The present invention further provides methods for determining the effect of mutations in VACV with regard to competence for replication in certain cell types. The present invention further provides methods of preparing modified vaccinia viruses.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.